Our Mission
We believe that systemic exposure to drugs, especially in dermatology, should be an exception. Our mission is to develop localized treatment options that match the efficacy of the best systemic drugs with the safety of local, topical administration
MEET OUR TEAM
Marina Shevachman, Ph.D. Sr. Director, Product Development
Marina has 15+ years of experience in drug development, commercial manufacturing, and expanding product portfolio. She has a wide experience in drug product submission with a proven record of FDA approvals. She joined the CAGE Bio team in 2018. Prior to joining CAGE Bio, she held senior-level scientist positions at Perrigo and Allergan.
Chase Corley, M.S. Scientist II, Product Development
Chase brings 10+ years of analytical chemistry and molecular biology research to the Research and Development team. Prior to joining CAGE Bio, he worked at UT Southwestern Medical Center researching sterol analytical chemistry in the Lipidomics Core Facility for Molecular Genetics. He received his M.S. from the University of North Texas in Biochemistry and Molecular Biology.
Jason Mars, M.S. Scientist I, Product Development
Jason brings 6+ years of experience with analytical
chemistry, commercial manufacturing, and product
formulation. Prior to joining CAGE Bio, Jason worked
with Alcon Pharmaceuticals and BioChroma Analytical
Labs developing analysis techniques, performing FDA
clinical investigations as an expert witness, and advising
on new pharmaceutical ventures as a consultant with the
Gerson Lehrman Group.
Elaine Campbell, M.S. Sr. Scientist, Product Development
Elaine joined CAGE Bio’s R&D team in March 2024, bringing 15+ years of molecular biology and assay development expertise. She holds an M.S. in Biotechnology from Stephen F. Austin State University. Previously, she worked at Alcon Laboratories on assay development and biomarker identification for Dry Eye disease, led early-phase biotherapeutics research at Boehringer Ingelheim, and guided ophthalmic formulation development at Novartis Pharmaceuticals.
Drew Sturtevant, Ph.D. Scientist III, Product Development
Dr. Sturtevant is an experienced analytical biochemist and molecular geneticist. He helps lead the development of CAGE Bio's CGB-500 and is an active member and advocate of the DFW life-science ecosystem. He received his Ph.D. from the University of North Texas and completed his Post-Doctoral training at UTSW Medical Center.
Patricia Oto, RPh, Quality and Regulatory Lead
Patti has 25+ years of executive leadership experience with regulatory and quality oversight. Prior to joining CAGE Bio, Patti served as the Senior Vice President of Regulatory Affairs and Quality Assurance at Chrono Therapeutics. She has held positions at Incline Therapeutics (acquired by The Medicines Company), Onyx Pharmaceuticals (Amgen), Corgentech (Anesiva), Coulter (Corixa, GlaxoSmithKline), Genentech (Roche), and Syntex. Patti has worked on global regulatory submissions in several therapeutic areas.
Shashwati Godbole, M.S. Program Manager
Shashwati joined CAGE Bio bringing in research and industry experience within the Medical Affairs Operations and Management space. She received her M.S. in Biotechnology from Northeastern University. Prior to joining CAGE Bio, she worked at Vertex Pharmaceuticals primarily supporting MSLs and product management teams along with congress planning, grants and external fundings.
Welcome! Check out our latest news.
CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis